Latest research on Insulin detemir

Insulin detemir is a long-acting human insulin analogue used to maintain basal levels of insulin in diabetic individuals. It is produced using recombinant DNA technology in yeast cells. This insulin analogue has a 14-C fatty acid, myristic acid, bound to the lysine amino acid at position B29. The myristoyl side chain increases self-association and albumin binding. This along with slow systemic absorption from the injection site prolongs distribution of the hormone into tissues and results in a long duration of action. Novo Nordisk markets insulin detemir under the trade name Levemir.

Insulin detemir side effects

Because neither Insulin detemir nor insulin glargine 100 U/ml are true 24‐h insulins in people with type 1 diabetes, a single injection may not provide full coverage in some individuals. [source, 2015]
This is because in the phenolic SEC eluent (similar to the pharmaceutical formulation), Insulin detemir elutes as a hexamer [11, 15], as does insulin Aspart, so the two insulin analogs (and any hybrid associations) would therefore be indistinguishable using this method. [source, 2015]
In the latter situation, the percentage of insulin Aspart eluting in the monomer–hexamer fraction decreased from 99 to 64%, implying that about a third of the insulin Aspart was associating into dihexameric structures with Insulin detemir. [source, 2015]
This problem has hitherto prevented the co-formulation of two different insulin analogs that have distinct and desired PK/PD profiles (e.g., Insulin detemir and insulin Aspart) because these profiles would have been compromised by such interactions. [source, 2015]
Long-acting basal analogs, such as insulin glargine, Insulin detemir, and insulin degludec, are preferable to neutral protamine Hagedorn because of their more physiological profiles and lower variability [73,74]. [source, 2015]
The logistic regression model identified the following factors as predictors of nocturnal asymptomatic hypoglycemia (each shown with its adjusted OR and 95% confidence interval): HbA1c (per 1% increase in HbA1c), 0.46, 0.25–0.84; total daily dose of insulin (per 1 U/kg increase in total daily dose of insulin), 75.1, 1.65–3418; and insulin glargine (vs. Insulin detemir), 6.93, 1.42–34.0. [source, 2015]
Oxidative stress due to increased glucose fluctuations has been proposed as one possible reason for an association between PPG levels and CVD, but a small (n = 43) trial comparing thrice-daily insulin Aspart versus once-daily Insulin detemir showed significantly lower measures of oxidative stress, based on urinary 8-iso-prostaglandin F2α only in the Insulin detemir group (p = 0.0079) [94]. [source, 2015]
Meanwhile, she developed episodes of hyperglycemia with increased HbA1c levels (up to 9.3 %) despite carbohydrate restricted diet, caused by insulin resistance, for which Metformin and Levemir were prescribed. [source, 2015]
However, some patients with extremely low insulin secretion capacity often need to use twice-daily basal insulin because the duration of action of Insulin detemir is about 16 hours [11] and that of insulin glargine does not last up to 24 hours [4, 12]. [source, 2015]
The proportion of patients at A1c goal decreased from 18 % with insulin glargine to 16 % with Insulin detemir. [source, 2015]